Trial Profile
An Active-Comparator Controlled Single Dose Study to Evaluate the Pharmacodynamics/Efficacy of MK7288 in Sleep Apnea Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs MK 7288 (Primary) ; Modafinil
- Indications Sleep apnoea syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 18 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 12 Mar 2014 New trial record